Table 1.
Baseline Characteristics (N = 13)
| Characteristic | No. (%)a |
|---|---|
| Age at diagnosis, mean (range), y | 55.6 (45–75) |
| Male sex | 7 (54) |
| Race | |
| White | 9 (69) |
| Hispanic | 3 (23) |
| Black | 1 (8) |
| Histology | |
| Papillary thyroid cancer | 10 (77) |
| Poorly DTC | 2 (15) |
| Follicular thyroid cancer | 1 (8) |
| Tumor genotype | |
| BRAF V600E | 9 (70) |
| NRAS/KRAS | 3 (23) |
| WT | 1 (7) |
| Prior RAI treatments, median (range), no. | 1 (0–3) |
| Cumulative administered activity, median (range), mCi | 163 (0–470) |
| Prior treatments for thyroid cancer | |
| Radiation therapy | 3 (23) |
| Reoperation | 9 (70) |
| Prior systemic therapyb | 4 (30) |
Abbreviation: WT, wild-type.
a
Unless otherwise indicated.
b
Prior systemic therapies include sorafenib, vemurafenib, and lenvatinib.